Susceptibility of Clinical Isolates of Enterobacteriaceae to BL-S640, a New Oral Cephalosporin
- 1 March 1975
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 7 (3) , 381-385
- https://doi.org/10.1128/aac.7.3.381
Abstract
The in vitro activity of BL-S640, a 7-(2-aryl-2-aminoacetamido)-3-(heterocyclic-thiomethyl) cephalosporin, was evaluated against 338 clinical isolates of Enterobacteriaceae in comparison with ampicillin, cephalothin, cefazolin, and cephalexin. Against Escherichia coli , BL-S640 was as active as cefazolin and more active than ampicillin, cephalothin, and cephalexin. BL-S640 was as effective as the other cephalosporins tested and far more active than ampicillin against Klebsiella and was more active than cephalexin against Proteus mirabilis and the indole-positive Proteus . The majority of Enterobacter, Serratia , and Citrobacter were resistant to ampicillin and all the cephalosporins tested. With rare exceptions, the zone of inhibition by the BL-S640 30-μg disk was either larger or the same as the zone obtained by the cephalothin 30-μg disk in the Kirby-Bauer disk susceptibility test.Keywords
This publication has 4 references indexed in Scilit:
- Clinical evaluation of cephradine, a new oral cephalosporinThe Lancet Healthy Longevity, 1974
- Drug susceptibility/resistance pattern of gram-negative uropathogens to seven cephalosporinsThe Lancet Healthy Longevity, 1973
- Cephalexin.1970
- Antibiotic susceptibility testing by a standardized single disk method.1966